847950-09-8

Basic information

• Product Name: PyriMido[5',4':5,6]pyriMido[1,2-a]benziMidazol-5(6H)-one, 6-(2,6-diMethylphenyl)-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]-
• Synonyms: PyriMido[5',4':5,6]pyriMido[1,2-a]benziMidazol-5(6H)-one, 6-(2,6-diMethylphenyl)-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]-;Lck Inhibitor;6-(2,6-Dimethylphenyl)-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-one
• CAS NO: 847950-09-8
• Molecular Formula: C31H30N8O
• Molecular Weight: 530.6229
• Mol File: 847950-09-8.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 809.1±75.0 °C(Predicted)
• Appearance: /
• Density: 1.36±0.1 g/cm3(Predicted)
• Solubility: Soluble in DMSO
• PKA: 7.87±0.42(Predicted)
• CAS DataBase Reference: PyriMido[5',4':5,6]pyriMido[1,2-a]benziMidazol-5(6H)-one, 6-(2,6-diMethylphenyl)-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]-(CAS DataBase Reference)
• NIST Chemistry Reference: PyriMido[5',4':5,6]pyriMido[1,2-a]benziMidazol-5(6H)-one, 6-(2,6-diMethylphenyl)-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]-(847950-09-8)
• EPA Substance Registry System: PyriMido[5',4':5,6]pyriMido[1,2-a]benziMidazol-5(6H)-one, 6-(2,6-diMethylphenyl)-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]-(847950-09-8)

Safety Data

• Hazardous Substances Data: 847950-09-8(Hazardous Substances Data)

Usage

Uses

TC-S 7003 is a novel, potent and orally active inhibitor of Lymphocyte Specific Kinase (Lck).

Upstream product

• 847950-98-5 6-(2,6-dimethylphenyl)-2-methanesulfonylbenzo[4,5]imidazolo[1,2-a]pyrimido[5,6-e]pyrimidin-5-one 
• 16153-81-4 4-(4-Methyl-piperazino)-anilin 

Relevant articles and documents

Structure-based design of novel 2-amino-6-phenyl-pyrimido[5′, 4′:5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): Synthesis, SAR, and in vivo anti-inflammatory activity

Lck, or lymphocyte specific kinase, is a cytoplasmic tyrosine kinase of the Src family expressed in T-cells and NK cells. Genetic evidence from knockout mice and human mutations demonstrates that Lck kinase activity is critical for T-cell receptor-mediated signaling, leading to normal T-cell development and activation. A small molecule inhibitor of Lck is expected to be useful in the treatment of T-cell-mediated autoimmune and inflammatory disorders and/or organ transplant rejection. In this paper, we describe the structure-guided design, synthesis, structure-activity relationships, and pharmacological characterization of 2-amino-6-phenylpyrimido[5′,4′:5,6]pyrimido[1,2- a]benzimidazol-5(6H)-ones, a new class of compounds that are potent inhibitors of Lck. The most promising compound of this series, 6-(2,6-dimethylphenyl)-2- ((4-(4-methyl-1-piperazinyl)phenyl)amino)pyrimido[5′,4′:5,6] pyrimido-[1,2-a]benzimidazol-5(6H)-one (25), exhibits potent inhibition of Lck kinase activity. This activity translates into inhibition of in vitro cell-based assays and in vivo models of T-cell activation and arthritis, respectively.